Cinclus Pharma
10.38
SEK
-1.14 %
Less than 1K followers
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-1.14%
-11.28%
-42.59%
-51.45%
-59.34%
-
-
-
-68.16%
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Read moreMarket cap
491.93M SEK
Turnover
213.51K SEK
Revenue
4.58M
EBIT %
-3,703.93 %
P/E
-
Dividend yield-%
-
Financial calendar
20/5
2025
Interim report Q1'25
22/5
2025
General meeting '25
20/8
2025
Interim report Q2'25
All
Webcasts
Press releases
ShowingAll content types
Cinclus Pharma publishes its Annual Report for 2024
Kallelse till årsstämma i Cinclus Pharma Holding AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Notice of Annual General Meeting in Cinclus Pharma Holding AB (publ)
Ny vetenskaplig artikel visar goda läkningsresultat för Cinclus Pharmas läkemedelskandidat linaprazan glurate för behandling av eGERD
New scientific article highlights good healing results for Cinclus Pharma's drug candidate linaprazan glurate for the treatment of eGERD
Redeye: Cinclus Pharma Q4 - Validation through market approval
Bokslutskommuniké januari – december 2024
Year-end report January – December 2024
Inbjudan till presentation av Cinclus Pharmas delårsrapport för fjärde kvartalet 2024
Invitation to presentation of Cinclus Pharma’s fourth quarter report 2024
Finansinspektionen: Flaggningsmeddelande i Cinclus Pharma Holding AB (publ)
Antal aktier och röster i Cinclus Pharma
Number of shares and votes in Cinclus Pharma
Linaprazan glurate får marknadsföringstillstånd i Kina
Linaprazan glurate receives marketing approval in China
Emission och återköp av C-aktier
Issue and repurchase of class C shares
